SCHEMBL5448369

SCHEMBL5448369

Cn1c[c]c2cc(OCc3ccccc3)ccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
KMT2A Q03164 2/20 0.53
SRD5A2 P31213 1/20 0.49
HRH3 Q9Y5N1 1/20 0.48
ALOX5 P09917 1/20 0.47
MAOB P27338 7/20 0.46
AS3MT Q9HBK9 1/20 0.46
ACSS2 Q9NR19 1/20 0.43
LMNA P02545 1/20 0.42
CYP1A2 P05177 1/20 0.42
PTGS1 P23219 1/20 0.42
SLC6A2 P23975 1/20 0.42
CYP2C19 P33261 1/20 0.42
PTGS2 P35354 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HIF1A Q16665 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
DYRK1A Q13627 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17956224 0.77 NPC1 (0.43) MEN1NPC1RAB9AKMT2ASRD5A2
SCHEMBL1400791 0.74 NPC1 (0.63) MEN1NPC1RAB9AKMT2ASRD5A2
SCHEMBL2176865 0.74 ALOX5 (0.58) MEN1NPC1RAB9AKMT2ASRD5A2
SCHEMBL17956239 0.72 CNR2 (0.55) MEN1NPC1RAB9AKMT2AHRH3
SCHEMBL7812504 0.70 NPC1 (0.52) MEN1NPC1RAB9AKMT2ASRD5A2
SCHEMBL7805459 0.70 NPC1 (0.49) MEN1NPC1RAB9AKMT2ASRD5A2
SCHEMBL28455666 0.70 RAB9A (0.49) MEN1NPC1RAB9AKMT2ASRD5A2
SCHEMBL1855831 0.70 MAOB (0.62) MEN1NPC1RAB9AKMT2ASRD5A2
SCHEMBL8544882 0.69 NPC1 (0.53) MEN1NPC1RAB9AKMT2ASRD5A2
SCHEMBL31068643 0.69 NPC1 (0.47) MEN1NPC1RAB9AKMT2ASRD5A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185079-A1 Therapeutic agents I ASTRAZENECA AB (SE) 2007-08-09 US disclosed
EP-1706384-A1 THERAPEUTIC AGENTS I AstraZeneca AB (SE) 2006-10-04 EP disclosed
WO-2005066132-A1 THERAPEUTIC AGENTS I ASTRAZENECA AB (SE) 2005-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185079-A1 Therapeutic agents I HTT, GRIN2A, GRIN1 MEN1 3515/4885NPC1 106/4885RAB9A 736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.